Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
NabumetonePDL I DEC / 13
Nadolol or its saltsPDL I DEC / 13
Nadroparin or its saltsPDL I DEC / 13
Nafarelin or its salts or derivativesPDL

Including but not limited to Nafarelin acetate.

I DEC / 13
Nafcillin or its salts or derivativesPDL

For veterinary use

I DEC / 13
Nalbuphine and any salt thereofC I JUN / 02
Nalidixic acidPDL I DEC / 13
Nalmefene or its saltsPDL I DEC / 13
Naloxegol or its saltsPDL

including but not limited to naloxegol oxalate

I JUN / 15
Naloxone hydrochloride injection,

when indicated for emergency use for opioid overdose

Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.

II FEB / 17
Naloxone hydrochloride nasal spray,

when indicated for emergency use for opioid overdose

Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.

II FEB / 17
Naloxone or its saltsPDL

including, but not limited to naloxone hydrochloride, except when indicated for emergency use for opioid overdose

I FEB / 17
Naltrexone or its salts PDL I DEC / 13
Naphazoline and its salts in nasal preparations for pediatric use II SEP / 98
Naphazoline and its salts. in nasal preparations for adult use and in ophthalmic products U
Naproxen or its salts

Except in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base).

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

I MAR / 15
Naproxen or its salts..

In preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes of the equivalent of 6,000 mg of naproxen base or less.

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

U MAR / 15
Naproxen or its salts..

In preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes exceeding the equivalent of 6,000 mg of naproxen base.

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

III MAR / 15
Naratriptan or its saltsPDL I DEC / 13
NatalizumabPDL I DEC / 13
Nateglinide or its salts or derivativesPDL I DEC / 13
Nebivolol or its salts or derivativesPDL I DEC / 13
NecitumumabPDL I APR / 17
Nedocromil or its saltsPDL I DEC / 13
Nefazodone or its saltsPDL I DEC / 13
NelarabinePDL I DEC / 13
Nelfinavir or its saltsPDL I DEC / 13
Neocinchophen or its saltsPDL I DEC / 13
Neomycin or its salts or derivativesPDL

Including but not limited to: Paromomycin sulfate (for veterinary use)

I DEC / 18
Neostigmine saltsPDL I DEC / 13
NepafenacPDL I DEC / 13
Neratinib or its salts PDL I OCT / 19
Nesiritide or its saltsPDL I DEC / 13
NetupitantPDL I DEC / 17
Nevirapine or its saltsPDL I DEC / 13
Niacin (nicotinic acid)

in extended-release formulations, except when sold in a modified-release oral dosage form that provides 500 milligrams or more per dosage unit or per daily dose

II MAR / 10
Nialamide or its saltsPDL I DEC / 13
NicarbazinPDL

For human use

I DEC / 13
Nicardipine or its saltsPDL I DEC / 13
Nicotine or its saltsPDL

For human use - EXCEPT: (a) in natural substances; (b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit; (c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day; (d) in a form to be administered into the oral cavity by means of a non-active device (one that operates on energy generated by the human body or by gravity) that delivers 4 mg or less of nicotine per dose for buccal absorption; or (e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit).

I AUG / 18
Nicotine or its saltsPDL

For veterinary use.

I DEC / 13
Nicotinic acidPDL

For human use - when sold in: (a) a modified-release oral dosage form that provides 500 milligrams or more per dosage unit or per daily dose; or (b) an immediate-release oral dosage form that provides more than 500 milligrams per dosage unit or per daily dose.

I DEC / 13
Nicotinyl-tartrate I SEP / 98
NifedipinePDL I DEC / 13
Nikethamide I SEP / 98
Nilotinib or its saltsPDL I DEC / 13
NilutamidePDL I DEC / 13
Nimodipine or its saltsPDL I DEC / 13
Nintedanib or its saltsPDL I AUG / 15
Niraparib or its salts PDL I OCT / 19
NitisinonePDL I NOV / 16
Nitric oxidePDL I DEC / 13
Nitrofurantoin or its saltsPDL

For human use.

I DEC / 13
Nitroglycerin

Except for sublingual immediate release dosage forms.

I SEP / 98
Nitroglycerin. sublingual immediate release dosage forms II SEP / 98
NitroscanatePDL I DEC / 13
NivolumabPDL I JAN / 16
Nizatidine and its saltsNR

When sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine.*

I SEP / 98
Nizatidine or its saltsPDL

Except when sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine.

I DEC / 13
Nomifensine or its saltsPDL I DEC / 13
Norepinephrine and its salts levarterenol, noradrenaline II SEP / 98
NorfloxacinPDL I DEC / 13
Nortriptyline or its saltsPDL I DEC / 13
Novobiocin or its salts or derivativesPDL

For human use.

I DEC / 13
NusinersenPDL I AUG / 17
Nylidrin or its saltsPDL I DEC / 13
Nystatin and its salts and derivatives. in topical preparations for use on the skin III SEP / 98
Nystatin or its salts or derivativesPDL

For human use - except preparations for topical use on the skin.

I DEC / 13

68 result(s)


Footnotes

  • C - Drug is listed in the Schedule to Part G of the Food and Drug Regulations under the Controlled Drugs and Substances Act
    N - Drug is listed in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
    NR - Drug has not been reviewed by the NDSAC
    PDL - Drug is listed in the Health Canada Prescription Drug List
    TS - Drug is listed in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
    CR - Drug has been recommended for addition to the Controlled Drugs and Substances Act